The phase III KEYNOTE-590 trial evaluating Keytruda in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer demonstrated a significant improvement in overall survival.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
